Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883864/
https://www.ncbi.nlm.nih.gov/pubmed/33579740
http://dx.doi.org/10.1136/jitc-2020-001622corr1
Descripción
Sumario:

Ejemplares similares